欧洲的癌症负担:对GLOBOCAN数据库 (2022) 的系统分析
Mohammed Elmadani1,2,3, Peter Onchuru Mokaya4, Ahmed A A Omer5
1Doctoral School of Health Sciences, Faculty of Health Sciences, University of Pecs, Vorosmarty Mihaly Street 4, Pecs, 7621, Hungary. madani@pte.hu.
BMC cancer
|March 13, 2025
概括
北欧和西欧的癌症发病率最高,而东欧的死亡率最高. 有针对性的公共卫生战略对于减少癌症负担和改善整个非洲大陆的早期检测至关重要.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 癌症在欧洲是一个重大的公共卫生挑战,在发病率,死亡率和医疗保健获取方面存在相当大的区域差异.
- 这项研究检查了2022年东欧,北欧,南欧和西欧的癌症模式,以确定公共卫生影响和预防和治疗方面的差异.
研究的目的:
- 分析2022年欧洲不同地区的癌症发病率和死亡率.
- 突出癌症负担的区域差异,并确定关键的公共卫生影响.
- 通过探索这些差异的决定因素,为基于证据的癌症控制政策提供信息.
主要方法:
- 利用GLOBOCAN 2022数据评估每10万新增癌症病例总数和年龄标准化发病率和死亡率 (ASR).
- 欧洲人口在75岁时计算的累积癌症风险.
- 根据性别和地区分析了前三种癌症,以确定趋势和差异.
主要成果:
- 欧洲在2022年记录了4,471,422例新的癌症病例 (ASR280/100,000),75岁时的累计风险为27.9%.
- 北欧和西欧的发病率最高,而东欧的死亡率最高 (ASR 135.3).
- 前列腺癌和乳腺癌是最常见的;肺癌死亡率最高,胰腺癌死亡率高.
结论:
- 癌症负担的显著区域差异需要有针对性的公共卫生战略,包括扩大查和改善东欧的医疗保健准入.
- 加强戒烟和HPV疫苗接种工作对于减少癌症死亡率和提高早期检测至关重要.
- 死亡率与发病率的差异凸显了医疗保健基础设施和及时干预癌症结果的重要性.
相关概念视频
01:21Cancer Survival Analysis
315
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
315
02:18Cancer
47.3K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
47.3K
01:20Actuarial Approach
50
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
50